Akiva Felt

Oppenheimer Calls Mallinckrodt's New Acthar Data 'Impressive,' Despite This Week's Turmoil

35 Stock Ideas Oppenheimer Analysts Love Right Now

Watch Out Biotech Investors: Outrage Culture + Election Season = Ugly Rhetoric Ahead

35 Stock Ideas Oppenheimer Analysts Love Right Now

Watch Out Biotech Investors: Outrage Culture + Election Season = Ugly Rhetoric Ahead

Oppenheimer: Time To Buy Tonix Pharmaceuticals

Analyst: Mylan Shareholders Might Get Convinced By Vigodman Letter

Oppenheimer: Time To Buy Tonix Pharmaceuticals

Analyst: Mylan Shareholders Might Get Convinced By Vigodman Letter

Exclusive: Oppenheimer Says Insys-Mallinckrodt Merger Not Any More Likely Than It Was 4 Months Ago

8 Oppenheimer Analysts Choose Their Favorite Healthcare Stocks

Akiva Felt Recent News

Oppenheimer: Teva Is Now Worth $77/Share, More Deals To Come

UPDATE: Oppenheimer Upgrades Zogenix Following Zohydro Approval

UPDATE: Oppenheimer Initiates Coverage on Cubist Pharmaceuticals on Strong Antibiotic Portfolio

Oppenheimer Reiterates Perform Rating on Amarin Following AMR-102 Study

UPDATE: Oppenheimer Assumes Zogenix at Perform on Fair Valuation

UPDATE: Oppenheimer Assumes Viropharma at Outperform on Expected Improvement Ahead

UPDATE: Oppenheimer Assumes Antares Pharma at Outperform on Multiple Positive Factors

UPDATE: Oppenheimer Assumes Endo Health Solutions at Perform on Operational Restructuring

UPDATE: Oppenheimer Initiates Amarin at Perform on Vascepa Potential

UPDATE: Oppenheimer Initiates Intercept Pharmaceuticals at Outperform on Bullish Outlook

UPDATE: Oppenheimer Assumes Medicines Company at Perform Rating on Valuation

UPDATE: Oppenheimer Assumes Questcor Pharmaceuticals at Outperform on Compelling Upside Potential